BioNTech

breast cancer mammogram

Biotech

BioNTech posts overall survival data on would-be Keytruda killer

BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial benchmark and supporting use in a broader population.

Nick Paul Taylor Dec 10, 2024 9:00am

steps race jump stairs climb

Chasing Merck, BioNTech, DualityBio post first data on ADC

Dec 6, 2024 9:07am

Illustration connected puzzle pieces with the acronym MA

BioNTech pays $800M to take control of potential Keytruda killer

Nov 13, 2024 6:45am

yellow traffic light

FDA puts partial hold on BioNTech-OncoC4 phase 3 trial

Oct 18, 2024 12:55pm

2 cancer biotechs merge, creating global footprint

Sep 25, 2024 10:54am

Go sign green light

FDA allows BioNTech-MediLink ADC trial to resume at lower doses

Aug 19, 2024 8:45am